As China’s Biotech Firms Shift Gears, Can AI Floor the Accelerator?

MoFo Shanghai and Hong Kong Managing Partner Chuan Sun was quoted in a feature story published by South China Morning Post. The story explores how China’s biotech companies are moving up the pharmaceutical value chain and whether AI could further accelerate that shift, taking an analytical approach with a balanced assessment of both the opportunity and the remaining innovation gap.

According to Chuan, “AI can help companies screen and select drug targets faster, design better clinical trial protocols and stress-test molecular candidates before they enter human trials.” He said, “Across the biotech ecosystem, more and more companies are actively exploring and adopting AI to varying degrees.”

Read the full article.